All In Biotech

NDA 021902 · Ani Pharms

Veregen

Sinecatechins · Topical

Novel

Last checked: Nov 19, 2026Latest source record: Dec 19, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Oct 31, 2006

Approved uses

2

Original approval plus efficacy supplements

Registered trials

10

4 Phase 3, 1 recruiting

FAERS reports

54

30 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 10, 2022.

Veregen is a topical ointment indicated for the treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older (1.1) . Limitations of Use Safety and effectiveness of Veregen have not been established in immunosuppressed patients, in treatment of external genital and perianal warts beyond 16-weeks, or for multiple treatment courses (1.2) . 1.1 Indication Veregen is indicated for the topical treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older. 1.2 Limitations of Use The safety and effectiveness of Veregen have not been established for treatment beyond 16-weeks or for multiple treatment courses. The safety and effectiveness of Veregen in immunosuppressed patients have not been established.

Mechanism: The mode of action of Veregen involved in the clearance of genital and perianal warts is unknown. In vitro, sinecatechins had anti-oxidative activity; the clinical significance of this finding is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • VEREGEN · SINECATECHINS 15% · OINTMENT, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sinecatechins" as an intervention, any sponsor and status, largest first.

All 10 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • cellulitis6
  • application site pain5
  • drug ineffective5
  • pain4
  • product use issue4
  • application site erythema3
  • erythema3
  • off label use3
  • pruritus3
  • rash3
  • application site discharge2
  • application site pruritus2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
20091
20101
20112
20122
20134
20152
20162
20171
201810
20198
20204
20212
20227
20233
20243
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Veregen (Sinecatechins)

2024 spending

$223K

Beneficiaries

70

126 claims

Per beneficiary

$3,189

$51.68 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$235,043
2024$223,245

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 13 on PubMed

Sponsor: Ani Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.